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Background: It is well-established that hypertensive disorders of pregnancy (HDP) are
associated with an increased risk of cardiovascular disease (CVD) in later life. National
and International guidelines recognize this but due to a lack of research in this area few
details are provided on how best to risk stratify or when and how tomonitor these women.
Objectives: This article aims to summarize current guidelines in this area in order to
raise awareness of need for further research in this important clinical area.
Search Strategy: A review of the published literature was carried out in August 2018
using the databases EMBASE and Medline and the websites of professional societies
were searchedmanually using the search terms “pre-eclampsia,” “hypertensive disorders
of pregnancy,” “management,” “guidelines,” “long term follow up” and “cardiovascular
risk.” Guidelines published in English were included and articles that provided guidance
on follow up post-partum of women with HDP.
Main Results: The search identified 360 records. Of these, 16 guidelines mentioned
the follow up of women with HDP; their reported years ranges from 2010 to 2018.
Only 8 (50%) provided some level of recommendation for follow up beyond the
immediate post-partum period. These recognized the future risk of CVD to women
from HDP and provide detailed recommendations for the management of these
conditions during pregnancy and in the immediate post-partum period. Guidelines
recommended that women and primary care clinicians are made aware of this
risk and some suggest yearly BP monitoring, and at least 5 yearly monitoring of
renal functions, urinalysis and lipid profile testing alongside lifestyle modifications
and control of CVD risk factors. Guidelines used a combination of meta-analysis,
individual cohort studies and expert opinions to inform their recommendations.
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Conclusions: There is a need for future studies of women with a history of HDP to
define their trajectory for the development of CVD and candidate biomarkers in order to
develop screening, risk stratification, and preventive measures to reduce the significant
CV burden associated with HDP in women.
Keywords: pre-eclampsia, hypertensive disorder of pregnancy, guidelines, cardiovascular disease, cardiovascular
disease in women
INTRODUCTION
Historically, hypertensive disorders of pregnancy (HDP) were
believed to be self-limiting with little effect on health once blood
pressure (BP) had returned to normal in the postnatal period. It
is now well-established that this group of conditions, comprising
gestational hypertension, pre-eclampsia and eclampsia, are
associated with an increased risk of cardiovascular disease (CVD)
in later life (1–3). CVD is one of the most important causes of
death in women and has a huge impact on healthcare costs; in
the UK the NHS spent more than $5.9 billion on heart disease
between 2013 and 2014 (4).
Pre-eclampsia in particular has been shown in a number of
systematic reviews andmeta-analyses to impact on the health and
well-being of women extending beyond pregnancy outcomes. A
systematic review and meta-analysis in women with prior pre-
eclampsia showed the relative risks [(95% CI) for heart failure
(HF) and CVD death to be 4.19 (2.09–8.38) and 2.21 (1.83–2.66),
respectively (1)]. In another systematic review and meta-analysis
the relative risks (95% CI) in women with prior pre-eclampsia
were 3.70 (2.70–5.05) for hypertension (HT), 2.16 (1.86–2.52)
for ischaemic heart disease (IHD) and 1.81 (1.45–2.27) for
stroke (2).
Some national and international guidelines recognize these
future risks and recommend routine follow up of women who
had suffered from HDP in order to prevent heart disease.
However, due to a lack of research in this area, few details are
provided on how best to do this. This article aims to summarize
current guidelines in this area in order to raise awareness of this
important clinical uncertainty.
Search Strategy/Methodology
A review of the published literature was carried out using
the databases EMBASE (1980–2018) and Medline (1946–
2018) and the websites of relevant professional societies such
as The National Institute for health and Care Excellence
(NICE), The European Society of Cardiology (ESC), The
Institute of Obstetricians and Gynecologists of Ireland and The
American college of Obstetricians and Gynecologists were hand-
searched in August 2018. The search was undertaken using
the search terms “pre-eclampsia,” “hypertensive disorders of
pregnancy,” “management,” “guidelines,” “long term follow up”
and “cardiovascular risk.” All of the relevant articles returned
were published between 2010 and 2018. Reference lists of
identified articles were also scrutinized. Guidelines published
in English (or with English translation) were included. Articles
that provided guidance on follow up of women with HDP post-
partum period were selected. The relevant data were collected
from the published full text. Databases were last searched on 5th
August 2018. The Prisma flow chart for guideline inclusion is
shown in Figure 1.
Summary tables of identified guidelines were developed to
outline details on referral to specialist teams, recommendations
for investigations, monitoring frequency and follow up time
and any other recommendations for risk factor modification
or preventative actions. The guidance was also scrutinized for
the level of evidence upon which these recommendations were
based and assigned a final grade for the quality of evidence
as “high,” “moderate,” “low,” or “very low” based on the
strength and quality of underlying evidence for the critically
important outcomes based on the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) principles.
This is also summarized.
RESULTS
Guidelines were summarized in Table 1, their recommendations
were divided specialist referral, recommendations for
investigations and monitoring frequency and follow up
time and risk factor modification and other preventative actions.
The graded level of underlying evidence was also specified.
The search identified 360 records. Of these, 16 guidelines
mentioned the follow up of women with HDP; their reported
year ranges from 2010 to 2018. Only 8 (50%) provided some
level of recommendation for follow up beyond the immediate
post-partum period.
Summary of Guidelines
UK
The National Institute for health and Care Excellence (NICE)
have issued clinical guideline 107 in 2011, titled Hypertension
in pregnancy: diagnosis and management (5). This guideline
provides detailed recommendations for the diagnosis and
management of HDP during the pregnancy, intrapartum and
immediate post-partum period. The guidance for follow up and
ongoing intervention following discharge is focused specifically
on those women who remain hypertensive or on hypertensive
medication. For these women, it recommends that information
should be provided to primary care including who will provide
medical review, frequency of BP monitoring and thresholds for
reducing or stopping treatment, although no specific details
are given. It also provides guidance on frequency of post-natal
and medical reviews for women who remain hypertensive and
suggests hematological and biochemical monitoring for those
with deranged blood tests on discharge or those who remain
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FIGURE 1 | Prisma flow chart of guideline inclusion.
proteinuric. It states that women who have had pre-eclampsia
should be offered a medical review at the 6–8 week postnatal
review, those who are still on antihypertensive treatment 2 weeks
after discharge should be offered a medical review and those
who still need antihypertensive treatment at the postnatal review
should be offered a specialist assessment of their hypertension.
However, whilst this guideline states that women who have had
gestational hypertension or pre-eclampsia should be informed
along with their primary care physicians that these conditions
are associated with an increased risk of developing hypertension
and its complications in later life, no details are provided
on how to monitor these women once they are off their
antihypertensive medication and their BP has normalized. It
does nonetheless recommend that women with a history of
pre-eclampsia who have no proteinuria and are normotensive
at the postnatal review require no further renal follow-up or
thrombophilia screening and that they should maintain a BMI
between 18.5 and 24.9 kg/m2, in line with NICE clinical guideline
43 titled Obesity prevention (22). NICE used a combination
of individual observational cohort and case control studies to
inform their recommendations. NICE are currently updating
their recommendations in this guideline including their advice
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on follow up care after transfer to community care. This updated
guidance is expected to be published in June 2019. The specific
recommendation in HDP have not been made available at the
time of writing.
In 2010, The National Collaborating Centre for Women’s and
Children’s Health (UK) issued a guidance titled “Hypertension in
Pregnancy: The Management of Hypertensive Disorders During
Pregnancy” (6). This echoes NICE CG 107 by recommending
women and their primary care doctors to be informed of
the future CVD risk. It highlights that there is insufficient
evidence for practitioners to provide recommendations on
the frequency of follow up. These Guidelines used meta-
analysis from Bellamy et al. (2) and Macdonald et al. (3)
for their recommendations as well as cohort studies by
Wilson et al. (23).
Europe
In 2018 the ESC issued guidelines for the management of
arterial hypertension (7). This recommends annual visits to a
primary care physician for BP checks and to other metabolic risk
factors. It also suggests previous hypertension in pregnancy or
pre-eclampsia should be part of a clinical history and lifestyle
modifications are indicated to reduce the risk of CVD in
the future.
The ESC has issued guidance on the management of
CVDs during pregnancy (8). Beyond the immediate post-
partum period, it recommends lifestyle modifications, regular
BP review and control of metabolic factors to mitigate
maternal cardiovascular risk in the future. These Guidelines
used meta-analysis from Macdonald et al. (3), cohort studies
from Wilson et al. (23) and the Effectiveness-based guidelines
for the prevention of CVD in women —2011 update: a
Guideline from the American Heart Association as the basis for
their recommendations.
The Institute of Obstetricians and Gynaecologists of Ireland
have issued clinical practice guideline no. 3 in 2016, titled
Diagnosis and management of severe pre-eclampsia and
eclampsia (9). Again, their recommendations post-partum
focuses on the immediate management of women with ongoing
hypertensive needs, recommending BP monitoring every 1–2
days for up to 2 weeks after discharge until antihypertensive
treatment has been discontinued and the patient is normotensive.
It does suggest that, all patients with severe pre-eclampsia
should be offered an appointment in secondary care within 3
months of delivery. Interestingly, the Institute of Obstetricians
and Gynaecologists of Ireland provides little specific details.
Other assessments, such as BP and proteinuria should also
be performed. This includes referral to specialist services
if antihypertensive treatment is ongoing and required or
proteinuria is confirmed. It echos the NICE guidelines with
regards to information that should be provided to primary care
following discharge. The same institution issued The Clinical
Practice Guideline no. 37 in 2016, titled the management
of hypertension in pregnancy (10); this recommends that
follow-up after 6 weeks post-partum is required to ensure
resolution of pregnancy-related changes and to determine the
need for ongoing care. It suggests those at high risk of
ongoing hypertension include those with chronic hypertension,
prolonged anti-hypertensive treatment, higher maximum BPs
during pregnancy, higher BMI and those with pre-eclampsia
that occurred preterm. Women with persistent hypertension
not previously assessed should undergo routine work-up and
be given advice regarding future lifestyle and optimization
of risk factors in subsequent pregnancies. This includes
those who are obese, have other cardiovascular risk factors,
secondary hypertension or end-organ disease. They gathered
evidence from Health professionals’ opinions for their specialist
referral, recommendations, risk factor modification, and other
preventative actions.
The French Society of Hypertension, an affiliate of the French
Society of Cardiology, issued an expert consensus statement on
hypertension and pregnancy in 2017 (11). This recommends that,
women with pre-eclampsia should be reviewed by a consultant
to ensure CVD and renal disease risk factors are identified
and controlled. It highlights that, regular monitoring, healthy
life style, and modulation of CVD risk factors is essential to
reducing CVD in the future. It also recommends communicating
effectively to the patient. It suggests that, women who have had
a hypertensive disorder of pregnancy should have the etiology of
the disease assessed and undergo BP, renal function and urinalysis
monitoring. They should also undergo long term BP monitoring,
even after their BP has normalized post-delivery. They derived
evidence from meta-analysis of observational studies by Bellamy
et al. (2) as well as from Health professionals’ opinions for
their recommendations.
North America
In 2017 the American College of Cardiology/American
Heart Association task force on clinical practice guidelines
issued guidance on the prevention, detection, evaluation, and
management of high blood pressure disorders in adults (13). This
stated that there was no evidence that blood pressure thresholds,
blood pressure targets, treatment choices, or antihypertensive
combinations should differ in women compared to men but
mentioned little else specific to women or HDP.
The American Heart Association and the American College
of Obstetricians and Gynecologists have issued guidance
titled “Promoting Risk Identification and Reduction of
Cardiovascular Disease in Women Through Collaboration
With Obstetricians and Gynecologists: A Presidential
Advisory From” in 2018 (12). This recognizes the need
for sex specific guidelines targeted to women. It provides
recommendations for cardiovascular prevention including
management for monitoring of hypertension, hyperlipidaemia,
diabetes, and healthy lifestyle advice. However, despite listing
HDP as an important risk factor for future CVD, specific
recommendations for those who have suffered HDP are not
provided other than yearly blood pressure checks with an
increased risk for high blood pressure (including those who
have suffered HDP). These recommendations are based on
US Preventive Services Task Force final recommendation
statement for high blood pressure in adults, which itself
is based on evidence synthesis of systematic reviews of
observational studies.
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The American Heart Association issued a guideline in
2011 titled effectiveness-based guidelines for the prevention of
CVD in women (15). This emphasizes the need for female
based guidelines and an individualized approach to managing
cardiovascular risk in women. In this guideline, a history of
pre-eclampsia or pregnancy-induced hypertension puts women
in a high risk category for CVD and it goes on to say that
pregnancy provides an opportunity to estimate a woman’s future
cardiovascular risk, for which pre-eclampsia may be an early
indicator. The guideline also states that women should be
referred post-partum to a primary care physician or cardiologist
to monitor and control cardiovascular risk factors and that
HDP should be part of a detailed cardiovascular history in any
setting. Whilst the guideline recognizes the building evidence
base that pre-eclampsia is an important cardiovascular risk factor
and acknowledges the need for future research in this field, it
does not provide any details on how to monitor or determine
the effectiveness of diagnostic and preventive interventions in
this critical group. They used meta-analysis of observational
studies such as Bellamy et al. (2) as the underlying evidence for
their recommendations.
The American college of Obstetricians and Gynaecologists
Task Force on Hypertension in Pregnancy issued a guidance
titled hypertension in pregnancy in 2013. This states that pre-
eclampsia, particularly if associated with pre-term delivery, is
a strong risk factor for CVD. It recommends that, women
should maintain a healthy lifestyle in terms of maintaining
an optimum body weight, consuming a diet high in fiber,
fruit and vegetables, and low in fat and to avoid tobacco.
Furthermore, it states that future CVD risk factors should be
considered and provides no further details regarding the timing
and frequency of these evaluations. They gathered evidence
from Health professionals’ opinions for their recommendations
on specialist referral, risk factor modification, and other
preventative actions.
The Guidelines for the Prevention of Stroke in Women,
a Statement for Healthcare Professionals from the American
Heart Association and American Stroke Association in 2014 (17)
recognizes the link between pre-eclampsia or eclampsia and CVD
and stroke outcomes. It states that, “insufficient evidence exists
to inform any recommendation for screening, prevention, or
treatment in womenwith a history of pregnancy complications or
adverse pregnancy outcomes.” It does however suggest that those
womenwith ongoing hypertension should bemanaged according
to adult guidelines. It also recommends women with a history
of pre-eclampsia or eclampsia should have this documented
as a risk factor and that these women should have common
CVD risk factors (including smoking and dyslipidaemia)
identified and treated. These guidelines used evidence from
meta-analysis of cohort studies including Macdonald et al. (3)
for their recommendations as well as the Wilson et al. (23)
cohort study.
The Association of Ontario Midwives issued clinical practice
guideline 15 in 2012, titled HDP (16). This recommends
that, midwives discuss the need for healthy lifestyle choices
with women post-delivery and provide information on
HDP to primary care physicians. They gathered evidence
from systematic reviews of observational studies including
Bellamy et al. (2) and Macdonald et al. (3) as well as
Health professionals’ opinions for the specialist referral,
recommendations, risk factor modification, and other
preventative actions.
The Society of Obstetricians and Gynaecologists of Canada
issued clinical practice guideline 307 titled Diagnosis, Evaluation,
and Management of HDP in 2014 (18). This echos NICE
clinical guideline 107 by providing details on review frequency,
treatment options and BP targets for the immediate 6 weeks
period post-partum. It provides some guidance on ongoing
care beyond 6 weeks, which again focuses predominantly on
those still requiring hypertensive medication or those with
persistently raised BP or deranged renal function. It states
that women with a history of severe pre-eclampsia should be
screened for underlying hypertension or renal disease and that
referral to internal or renal medicine should be considered
in those women with refractory post-partum hypertension or
indicators of renal disease (e.g., proteinuria) beyond 3–6 months.
It reveals that, those women with underlying hypertension
or persistent postpartum hypertension should undergo
urinalysis, renal function and electrolytes, fasting glucose,
fasting lipids and 12-lead electrocardiography at least 6 weeks
post-partum. It also reveals that, women who are normotensive
at discharge may benefit from assessment of cardiovascular
risk factors and all women who have had a hypertensive
disorder of pregnancy should maintain a healthy diet,
lifestyle, and BMI. These guidelines used a blend of individual
observational cohort and case control studies to inform
their recommendations.
Australia and New Zealand
The SOMANZ Guideline for the Management of HDP published
by the Society of Obstetric Medicine of Australia and New
Zealand in 2014 (19). This recommends that, women would
benefit from a healthy lifestyle which includes: a healthy weight,
smoking cessation program, exercise and a healthy diet. It also
recommends that, these women should have an annual BP check
and 5 yearly assessments of CVD risk factors including serum
glucose and lipid profiles. The SOMANZ guidelines used a
literature review as their evidence for lifestyle recommendations,
the literature review referenced Bellamy et al. (2) meta-analysis
as their evidence. They also used expert opinions to develop
their recommendations.
The Queensland Maternity and Neonatal Clinical Guidelines
Program issued Guideline No. MN10.13.V4-R15 in 2010, titled
HDP (20). This recommends women to undergo screening
for pre-existing hypertension and underlying renal disease,
cardiovascular risk factors (e.g., BP, lipid profile, and serum
glucose) and the necessity of women regularly assessed.
According to them, women should also maintain a healthy
lifestyle with their diet choice, exercise, and avoid tobacco.
The Queensland Maternity and Neonatal Clinical Guidelines
recommendations for investigations and monitoring BP used
The National Collaborating Centre (NCC) 2011 revised version;
The NCC referenced Bellamy et al. (2)’s work, to support
their recommendations.
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DISCUSSION
This is the first summary of current international guidelines
evaluating long term follow up for women who have suffered
HDP. Whilst all guidelines recognize the higher risk of CVD in
those with these conditions, and in the most part recommend
informing women and their general practitioner or family
doctors (GPs) of this, there is no consensus regarding who
to monitor intensively, for how long or how frequently and
what parameters should be used for screening initially and
perhaps at a future at risk period. Guidelines issued by obstetrics
and gynecological societies focus on the management and
identification of HDP during pregnancy and the immediate
postpartum period. Few details are given regarding timing and
frequency of monitoring, appropriate physical, and biomarkers
for longer term monitoring or strategies for the prevention of
CVD in later life. Guidelines issued by cardiological societies are
more explicit with some recommending yearly BP monitoring,
and at least 5 yearly renal functions, urinalysis and dyslipidaemia
testing. Some also recommend lifestyle modifications to achieve
a healthy weight, smoking cessation, and control of glucose and
lipid profiles. The most detailed recommendations for future
follow up comes from the ESC, Institute of Obstetricians and
Gynecologists Ireland, The American College of Obstetricians
and Gynaecologists, the American Heart Association and The
SOMANZ Guidelines. They recommend up to yearly BP
monitoring and yearly assessment of CVD risk factors. These
guidelines used the highest available level of evidence from
meta-analysis as well as specialist opinions from healthcare
professionals to inform their recommendations. Interestingly,
the ESC guidelines also make reference to the use of N-
terminal pro-B natriuretic peptide (NT-proBNP) as part of an
investigative work up for patients with hypertensive emergencies,
including pre-eclampsia. NT-proBNP has been shown to be
strongly related to cardiovascular events (24). Measurement
of such biomarkers in women with prior HDP needs further
evaluation as a potential predictor or tool to risk stratify for future
cardiovascular events.
Guidelines used a variety of levels evidence to inform
their recommendations. Many sited expert opinions as their
underlying evidence; including The Institute of Obstetricians
and Gynaecologists Ireland Clinical Guidelines 2010 and 2016
and The American College of Obstetricians and Gynaecologists
Task Force on Hypertension in Pregnancy (14). The report from
the American College of Cardiology (2017) used prospectively
designed overviews of randomized trials. The ESC and the
European Society of Hypertension (ESH) used retrospective
cohort studies for their recommendations. The Society of
Obstetricians and Gynaecologists Canada Clinical Practice
Guideline 307 (2014) and NICE (2011) used a blend of
individual observational cohort and case control studies as
underlying evidence to their recommendations. A number of
guidelines referenced the meta-analysis of Bellamy et al. (2),
Macdonald et al. (3) and cohort studies by Wilson et al. (23).
These included the French Society of Cardiology (2017), the
American Heart Association (2011), The Association of Ontario
Midwives Clinical Practice (2012), the SOMANZ guidelines
and The Queensland Maternity and Neonatal Clinical. Whilst
a number of guidelines used the highest available evidence,
namely the meta-analysis of observational studies by Bellamy
et al. (2) and Macdonald et al. (3) these studies focus primarily
on describing the association between HDP and future CVD
risk. There is still little high level evidence on how or when
to initiate follow up on these women and no evidence on
the effectiveness of recommended strategies in this unique
patient population. This clinical area falls between obstetrics
and gynecology and cardiology and general practitioners are
perhaps best placed to follow up these high risk women once
they are discharged into the community following the birth of
their baby.
This article has a number of strengths. We have systematically
reviewed all current English language guidelines on this
subject, capturing the majority of major international guideline
committees, and it is clear that there is an overwhelming paucity
ofrecommendations for how to manage women with previous
HDP going forward into later life.
This article has limitations that should be discussed. We have
only included English language guidelines and it is possible that
guidelines exist in other languages. Nonetheless, as we have
captured the major international guideline committees on this
subject it is unlikely that the guidelines that exist will change the
overall conclusions of this article. As this is a review of clinical
guidelines not clinical practice, it is possible that individual
centers have their own protocols and clinical strategies not
captured here. However, this is a novel and expanding area
and it is likely most clinical centers will be influenced by these
guidelines. It is possible that guidelines are influenced by the
opinions and clinical experience of the guideline development
group and not just the available objective evidence. However,
we have captured large globally influential guideline groups and
their opinions should be considered relevant and expert on
this subject.
We have systematically searched for guidelines published
in peer reviewed journals and by major professional societies
using transparent inclusion and exclusion criteria agreed
a priori. However, these were limited to English language
publications or translations only. We have summarized the
relevant guidance from the clinical guidelines and evaluated
the evidence underpinning the recommendations. This process
has highlighted gaps and uncertainties in clinical guidance
on how to manage women who have had HDP in the
longer term in order to monitor and mitigate their risk
of CVD. Further research needs to address the following
clinical questions:
• When should we start to monitor women with HDP after
being discharged in the community following normalization
of their BP?
• When and how frequently should women with HDP be
monitored if their BP has returned to normal?
• What investigations should form part of their monitoring to
maximize the chance of early detection of CVD risk?
• What interventions are effective in reducing the risk of
subsequent CVD in women with HDP?
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Once we have accumulated the evidence base from robust
research, clinical guidelines should follow. Clinical guidelines are
important in changing practice and behavior (25) provided they
are consistent and based on clear evidence.
CONCLUSION
Whilst these guidelines recognize the future risk to women
from HDP and deal appropriately with management of
these conditions during pregnancy and in the immediate
period post-partum there is a paucity of recommendations
for how to manage these women going forward. There is
a need for high quality studies of women with a history
of HDP to define their trajectory for the development of
CVD and then to develop screening, risk stratification, and
preventive measures.
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